

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/627,206
				<b>Filing Date</b>	July 27, 2000
				<b>First Named Inventor</b>	Jane A. Gross
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Robert A. Zeman
Sheet	1	of	15	<b>Attorney Docket Number</b>	05558.0026.CPUS03

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code <sup>2</sup> (if known)			
	A1	4,331,647	05-25-1982	Goldenberg	
	A2	4,486,533	12-04-1984	Lambowitz	
	A3	4,579,821	04-01-1986	Palmiter, et al.	
	A4	4,599,311	07-08-1986	Kawasaki	
	A5	4,601,978	06-22-1986	Karin	
	A6	4,615,974	10-07-1986	Kingsman, et al.	
	A7	4,656,134	04-07-1987	Ringold	
	A8	4,661,454	04-28-1987	Botstein, et al.	
	A9	4,713,339	12-15-1987	Levinson, et al.	
	A10	4,784,950	11-15-1988	Hagen, et al.	
	A11	4,845,075	07-04-1989	Murray, et al.	
	A12	4,870,008	09-26-1989	Brake	
	A13	4,882,279	11-21-1989	Cregg	
	A14	4,931,373	06-05-1990	Kawasaki, et al.	
	A15	4,935,349	06-19-1990	McKnight, et al.	
	A16	4,946,778	08-07-1990	Ladner, et al.	
	A17	4,956,288	09-11-1990	Barsoum	
	A18	4,977,092	12-11-1990	Bitter	
	A19	4,990,446	02-05-1991	Oberto, et al.	
	A20	5,037,743	08-06-1991	Welch, et al.	
	A21	5,063,154	11-05-1991	Fink, et al.	
	A22	5,139,936	08-18-1992	Botstein, et al.	
	A23	5,143,830	09-01-1992	Holland, et al.	
	A24	5,155,027	10-13-1992	Sledziewski, et al.	
	A25	5,162,222	11-10-1992	Guarino, et al.	
	A26	5,162,228	11-10-1992	Sumino, et al.	
	A27	5,208,146	05-04-1993	Irie	
	A28	5,223,409	06-29-1993	Ladner, et al.	
	A29	5,403,484	04-04-1995	Ladner, et al.	
	A30	5,523,227	06-04-1996	Bram, et al.	
	A31	5,541,291	07-30-1996	Keene	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds codes of USPTO Patent Documents as [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAZ/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/627,206
				<b>Filing Date</b>	July 27, 2000
				<b>First Named Inventor</b>	Jane A. Gross
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Robert A. Zeman
Sheet	2	of	15	<b>Attorney Docket Number</b>	05558.0026.CPUS03

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code <sup>2</sup> (if known)			
	A32	5,567,584	10-22-1996	Sledziewski, et al.	
	A33	5,571,698	11-05-1996	Ladner, et al.	
	A34	5,595,721	01-21-1997	Kaminski, et al.	
	A35	5,637,677	06-10-1997	Greene, et al.	
	A36	5,650,550	07-22-1997	Korach, et al.	
	A37	5,693,762	12-02-1997	Queen, et al.	
	A38	5,716,808	02-10-1998	Ramond	
	A39	5,736,383	04-07-1998	Raymond	
	A40	6,015,801	01-18-2000	Daifotis, et al.	
	A41	6,316,222	11-13-2001	Bram, et al.	
	A42	6,500,428	12-31-2002	Bram, et al.	
	A43	6,537,540	03-25-2003	Burstein, et al.	
	A44	6,774,106	08-10-2004	Theill, et al.	
	A45	6,716,576	04-06-2004	Yu, et al.	
	A46	7,501,497	03-10-2009	Mangelsdorf, et al.	

U.S. PUBLICATION DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code <sup>2</sup> (if known)			
	A47	2003-0022233	01-30-2003	Goodwin, et al.	
	A48	2003-0103986	06-05-2003	Rixon, et al.	
	A49	2004-0013674	01-22-2004	Ambrose, et al.	
	A50	2005-0070689	03-31-2005	Dixit, et al.	
	A51	2005-0183148	08-18-2005	Bram, et al.	
	A52	2006-0034852	02-16-2006	Rixon, et al.	
	A53	2006-0067933	03-30-2006	Gross, et al.	
	A54	2006-0073146	04-06-2006	Ashkenazi, et al.	
	A55	2006-0286093	12-21-2006	Gross, et al.	
	A56	2007-0071760	03-29-2007	Broly, et al.	
	A57	2007-0264689	11-15-2007	Gross, et al.	
	A58	2007-0269443	11-22-2007	Kalled, et al.	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAZ/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/627,206
				<b>Filing Date</b>	July 27, 2000
				<b>First Named Inventor</b>	Jane A. Gross
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Robert A. Zeman
Sheet	3	of	15	<b>Attorney Docket Number</b>	05558.0026.CPUS03

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T276
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	B1	AU 2006201471	05-04-2006	Genentech, Inc.		
	B2	EP 1666052	06-07-2006	Genentech, Inc.		
	B3	GB 9828628.9	12-23-1998	Glaxo Group Limited		
	B4	WO 91/11465	08-08-1991	Immunomedics, Inc.		
	B5	WO 94/06463	03-31-1994	Smith-Kline Beecham Corporation		
	B6	WO 94/09137	04-28-1994	Genentech, Inc.		
	B7	WO 95/35501	12-28-1995	The Board of Trustees of the Leland Stanford Junior University		
	B8	WO 96/18641	06-20-1996	Weinwurzel, H.		
	B9	WO 96/27011	09-06-1996	Genetech, Inc.		
	B10	WO 97/009137	03-13-1997	BBS KraftFahrzeugtechnik AG		
	B11	WO 97/17450	05-15-1997	Zymogenetics, Inc.		
	B12	WO 97/17451	05-15-1997	Zymogenetics, Inc.		
	B13	WO 98/02536	01-22-1998	Zymogenetics, Inc.		
	B14	WO 98/02565	01-22-1998	Zymogenetics, Inc.		
	B15	WO 98/39361 (Corrected Version)	09-11-1998	St. Jude Children's Research Hospital		
	B16	WO 99/04001	01-28-1999	Zymogenetics, Inc.		
	B17	WO 99/12964	03-18-1999	Biogen, Inc.		
	B18	WO 00/39295	07-06-2000	Glaxo Group Limited		
	B19	WO 00/03995	01/27/2000	Bayer Aktiengesellschaft		
	B20	WO 00/40714	07-13-2000	Oligos Etc. Inc.		
	B21	WO 00/40716	07-13-2000	Zymogenetics, Inc.		
	B22	WO 00/50597	08-31-2000	Human Genome		

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAZ/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/627,206
				<b>Filing Date</b>	July 27, 2000
				<b>First Named Inventor</b>	Jane A. Gross
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Robert A. Zeman
Sheet	4	of	15	<b>Attorney Docket Number</b>	05558.0026.CPUS03

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T276
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
				Sciences, Inc.		
	B23	WO 00/67034	11-09-2000	Immunex Corporation		
	B24	WO 01/60397	08-23-2001	Genentech, Inc.		
	B25	WO 01/77342	10-18-2001	Genentech, Inc.		
	B26	WO 01/81417	11-01-2001	Biogen, Inc.		
	B27	WO 01/87977	11-22-2001	Amgen Inc.		
	B28	WO 02/14504	02-21-2002	Kirin Beer Kabushiki Kaisha, et al.		
	B29	WO 02/38766	05-16-2002	Zymogenetics, Inc.		
	B30	WO 02/66516	08-29-2002	Zymogenetics, Inc.		
	B31	WO 02/94852 A2	11-28-2002	Zymogenetics, Inc.		
	B32	WO 03/01877	01-09-2003	Gene Logic, Inc.		
	B33	WO 03/14294	02-20-2003	Genentech, Inc.		
	B34	WO 03/55979	07-10-2003	Human Genome Sciences, Inc.		
	B35	WO 05/05462	01-20-2005	Genentech, Inc.		
	B36	WO 05/42009	05-12-2005	Biogen IDEC MA Inc.		
	B37	WO 06/52493	05-18-2006	Genentech, Inc.		
	B38	WO 06/68867	06-29-2006	Genentech, Inc.		
	B39	WO 07/134326	11-22-2007	Ares Trading S.A.		
	B40	WO 07/19573 A2	02-15-2007	Zymogenetics, Inc.		
	B41	WO 07/19575 A2	02-15-2007	Zymogenetics, Inc.		
	B42	WO 07/19618	02-22-2007	Garvan Institute of Medical Research		
	B43	PCT/JP01/06944 (WO 2002/014504)	02/21/2002	Kirin Beer Kabushiki Kaisha	Abstract	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAZ/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>		
				<b>Application Number</b>	09/627,206	
				<b>Filing Date</b>	July 27, 2000	
				<b>First Named Inventor</b>	Jane A. Gross	
				<b>Group Art Unit</b>	1645	
				<b>Examiner Name</b>	Robert A. Zeman	
<b>Attorney Docket Number</b>	05558.0026.CPUS03					
Sheet	5	of	15			

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T <sup>2</sup>	
	C1	<b>Altschul, et al.</b> , Bull Math. Bio., Vol. 48, pp. 603-666 (1986)		
	C2	<b>Anolik, J.H., et al.</b> , "New Treatments for SLE: Cell-Depleting and Anti-Cytokine Therapies," Best Practice & Research Clinical Rheumatology, Vol. 19, No. 5, pp. 859-878 (2005)		
	C3	<del>Anonymous, "Waldenström Macroglobulinemia," Wikipedia: The Free Encyclopedia, <a href="http://en.wikipedia.org/wiki/Waldenström_macroglobulinemia">http://en.wikipedia.org/wiki/Waldenström_macroglobulinemia</a></del>		
	C4	<b>Aviv, H., et al.</b> , "Purification of Biologically Active Globin Messenger RNA by Chromatography on Oligothymidylic acid Cellulose," Proc. Natl. Acad. Sci., Vol. 69, pp. 1408-1412 (1972)		
	C5	<b>Bairoch, A.</b> , "The PROSITE Dictionary of Sites and Patterns in Proteins, Its Current Status," Nucleic Acids Research, Vol. 21, No. 13, pp. 3097-3103 (1993)		
	C6	<b>Barlogie, B., et al.</b> , "Extended Survival in Advanced and Refractory Multiple Myeloma After Single-Agent Thalidomide: Identification of Prognostic Factors in a Phase 2 Study of 169 Patients, Blood, Vol. 98, No. 2, pp.492-494 (2001)		
	C7	<b>Bell, E.</b> , "TNF-R Homologues in Autoimmune Disease," Immunology Today, Vol. 21, No. 6, p. 253 (June 1, 2000)		
	C8	<del><b>Brisborough, J., et al.</b>, "FAcOg Prevents the Development of Airway Hyper-Responsiveness in a Murine Model of Asthma," pp. 1-24</del>		
	C9	<b>Biosis Database, [online]</b> , Biosciences Information Service, Philadelphia, PA (September 2008). Carbonatto, Michela, et al., "Nonclinical Safety, Pharmacokinetics, and Pharmacodynamics of Atacicept, Database Accession No. PRV200800586339, Toxicological Sciences, Vol. 105, No. 1, pp. 200-210 (Sept. 2008)		
	C10	<b>Bird, et al.</b> , Science, Vol. 242, p. 423 (1988)		
	C11	<b>Birren, et al.</b> , EMBL Database Report for Accession No. AC003958, January 6, 1998 (XP-002072294)		
	C12	<b>Bodmer, et al.</b> , "The Molecular Architecture of the TNF Superfamily," TRENDS in Biochemical Sciences, Vol. 27, No. 1, pp. 19-24 (Jan 2002)		
	C13	<b>Bonning, et al.</b> , J. Gen. Virol., Vol. 75, pp. 1551-1556 (1994)		
	C14	<b>Bram, R.J. and G.R. Crabtree</b> , "Calcium Signalling in T Cells Stimulated by a Cyclophilin B-Binding Protein," Nature, Vol. 371, pp. 355-358 (September 22, 1994)		
	C15	<b>Bram, R.J., et al.</b> , "Identification of the Immunophilins Capable of Mediating Inhibition of Signal Transduction by Cyclosporin A and FK506: Roles of Calcineurin Binding and Cellular Location," Molecular and Cellular Biology, Vol. 13, No. 8, pp. 4760-4769 (Aug. 1993)		
	C16	<b>Brenner, S., et al.</b> , "Errors in Genome Annotation," Trends in Genetics, Vol. 15, pp. 132-133 (1999)		

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAZ/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/627,206
				<b>Filing Date</b>	July 27, 2000
				<b>First Named Inventor</b>	Jane A. Gross
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Robert A. Zeman
Sheet	6	of	15	<b>Attorney Docket Number</b>	05558.0026.CPUS03

	C17	<b>Burgess, et al.</b> , "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," Journal of Cell Biology 111, pp. 2129-2138 (November 1990)	
	C18	<b>Carter, et al.</b> , Proc. Nat. Acad. Sci., Vol. 89, p. 42875 (1992)	
	C19	<b>Chan, A., et al.</b> , "Rescue Therapy Anti-CD20 Treatment in Neuroimmunologic Breakthrough Disease," J. Neurol. Vol. 254, pp. 1604-1606 (2007)	
	C20	<b>Chazenbalk, Rapport</b> , J. Biol. Chem., Vol. 270, pp. 1543-1549 (1995)	
	C21	<b>Cheema, G., et al.</b> , "Elevated Serum B Lymphocyte Stimulator Levels in Patients With Systemic Immune-Based Rheumatic Diseases," Arthritis & Rheumatism, Vol. 44., No. 6, pp. 1313-1319 (2001)	
	C22	<b>Cheson, B., et al.</b> , "National Cancer Institute-Sponsored Working Group Guidelines for Chronic Lymphocytic Leukemia: Revised Guidelines for Diagnosis and Treatment," Blood, Vol. 87, No. 12, pp. 4990-4997 (1996)	
	C23	<b>Chirgwin, et al.</b> , Biochemistry, Vol. 18, pp. 52-94 (1979)	
	C24	<b>Ciccarone, et al.</b> , Focus, Vol. 15, p. 80 (1993)	
	C25	<b>Claros, M.G., et al.</b> , Comput. Appl. Biosci., Vol. 10, pp. 685-686 (1994)	
	C26	<b>Clipstone, N.A. and G.R. Crabtree</b> , "Identification of Calcineurin as a Key Signalling Enzyme in T-lymphocyte Activation," Nature, Vol. 357, pp. 695-697 (June 25, 1992)	
	C27	<b>Corsaro, Pearson</b> Somatic Cell Genetics, Vol. 7, p. 603 (1981)	
	C28	<b>Cosman</b> , Stem Cells, Vol. 12, pp. 440-455 (1994)	
	C29	<b>Courtenay-Luck, et al.</b> , "Genetic Manipulation of Monoclonal Antibodies, Cambridge University Press article, "Monoclonal Antibodies, Production, Engineering and Clinical Application," p. 166 (1995)	
	C30	<b>Crabtree and Clipstone</b> , Annu. Rev. Biochem., Vol. 63, pp. 1045-1083 (1994)	
	C31	<del><b>Dall'Era, M., et al.</b>, "Atacicept Reduces B Lymphocytes and Immunoglobulin Levels in Patients with Systemic Lupus Erythematosus (SLE)," pp. 1-35</del>	
	C32	<b>Database Accession No. 014836</b> , "Tumor Necrosis Factor Receptor Superfamily Member 13B" (2007)	
	C33	<b>Database Accession No. P20333</b> , "Tumor Necrosis Factor Receptor 2 Precursor," (1995)	
	C34	<b>Davidson and Diamond</b> , "Autoimmune Diseases," N Engl J Med, Vol. 345, No. 5, pp. 340-350 (August 2, 2001)	
	C35	<b>DiLillo, D.J., et al.</b> , "Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice," The Journal of Immunology, Vol. 180, pp. 361-371 (2008)	
	C36	<b>Ding and JONES</b> , "Belimumab Human Genome Sciences/Cambridge Antibody Technology," Current Opinion in Investigational Drugs, Vol. 7, No. 5, pp. 464-472 (2006)	
	C37	<b>Do, R.</b> , "Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response." J. Exp. Med., Vol. 192, No. 7, pp. 953-964 (2000)	
	C38	<b>Durfee, T., et al.</b> , Genes Dev., Vol. 7, pp. 555-569 (1993)	
	C39	<b>Dynan, T.</b> , Nature, Vol. 316, pp. 774-78 (1985)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAZ/**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/627,206
				<b>Filing Date</b>	July 27, 2000
				<b>First Named Inventor</b>	Jane A. Gross
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Robert A. Zeman
Sheet	7	of	15	<b>Attorney Docket Number</b>	05558.0026.CPUS03

	C40	<b>Eisen</b> , "Aberrant Immune Responses," General Immunology, J.B. Lippincott Company, pp. 215-225 (1990)	
	C41	<b>Emmel, E.A., et al.</b> , "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation," Science, Vol. 246, pp. 1617 - 1620 (December 22, 1989)	
	C42	<b>European Search Report</b> of EP 05020384.3 dated April 27, 2007	
	C43	<b>European Search Report</b> of EP 03016020 dated July 10, 2003	
	C44	<b>European Search Report</b> of EP 05018984 dated January 25, 2006	
	C45	<b>European Search Report</b> of EP 05018985 dated January 16, 2006	
	C46	<b>European Supplementary &amp; Partial Search Report</b> of EP 02734478 dated December 7, 2007	
	C47	<b>Falk, et al.</b> , "The Systemic Amyloidoses," N Engl J Med, Vol. 337, No. 13, pp. 898-909 (Sept 25, 1997)	
	C48	<b>Feldmann</b> and Maini, "The Role of Cytokines in the Pathogenesis of Rheumatoid Arthritis," Rheumatology, Vol. 38, Suppl. 2, pp. 3-7 (1999)	
	C49	<b>Feldmann, et al.</b> , "Evaluation of the Role of Cytokines in Autoimmune Disease: The Importance of TNF $\alpha$ in Rheumatoid Arthritis," Progress in Growth Factor Research, Vol. 4, pp. 247-255 (1992)	
	C50	<b>Fiering, S., et al.</b> , "Single Cell Assay of a Transcription Factor Reveals a Threshold in Transcription Activated by Signals Emanating from the T-cell Antigen Receptor," Genes & Development, Vol. 4, pp. 1823-1834 (1990)	
	C51	<b>Friedman, J. and I. Weissman</b> , "Two Cytoplasmic Candidates for Immunophilin Action Are Revealed by Affinity for a New Cyclophilin: One in the Presence and One in the Absence of CsA," Cell, Vol. 66, pp. 799-806 (August 23, 1991)	
	C52	<b>Gao, X., et al.</b> , "Advanced Transgenic and Gene-Targeting Approaches," Neurochemical Research, Vol. 24, No. 9, pp. 1181-1188 (1999)	
	C53	<b>Garnier, et al.</b> , Cytotechnol., Vol. 15, pp. 145-155 (1994)	
	C54	<b>Ginzler, et al.</b> , "Safety Pharmacokinetic and Pharmacodynamic Results of a Phase 1 Single and Double Dose-Escalation Study of LymphoStat-B (Human Monoclonal Antibody to BLYS) in SLE Patients," American College of Rheumatology Abstract Supplement, pp. S377 (2003)	
	C55	<b>Gleeson, et al.</b> , J. Gen. Microbiol., Vol. 132, pp. 3459-3465 (1986)	
	C56	<b>Gotz-Ulrich, et al.</b> , Science, Vol. 278, pp. 138-141 (1992)	
	C57	<b>Graham, et al.</b> , J. Gen. Virol., Vol. 36, pp. 59-72 (1977)	
	C58	<b>Graham, Van der EB</b> , Virology, Vol. 52, p. 456 (1973)	
	C59	<b>Grantham, et al.</b> , Nuc.Acids Res., Vol. 8, pp. 1893-1912 (1980)	
	C60	<b>Green, et al.</b> , Nat. Genet, Vol. 7, p. 13 (1994)	
	C61	<b>Groom, J., et al.</b> , "Association of BAFF/Blys Overexpression and Altered B Cell Differentiation with Sjogren's Syndrome," The Journal of Clinical Investigation, Vol. 109, No. 1, pp. 59-68 (2002)	
	C62	<b>Grosjean, Fiers</b> , Gene, Vol. 18, pp. 199-209 (1982)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAZ/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/627,206
				<b>Filing Date</b>	July 27, 2000
				<b>First Named Inventor</b>	Jane A. Gross
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Robert A. Zeman
Sheet	8	of	15	<b>Attorney Docket Number</b>	05558.0026.CPUS03

	C63	<b>Gross, J., et al.</b> , "TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease: Impaired B Cell Maturation in Mice Lacking BlyS," Immunity, Vol. 15, pp. 289-302 (2001)	
	C64	<b>Grussenmeyer, et al.</b> , Proc. Natl. Acad. Sci., Vol. 82, pp. 7952-7954 (1985)	
	C65	<b>Haas, et al.</b> , Cur. Biol., Vol. 6, pp. 315-324 (1996)	
	C66	<b>Hahne, M., et al.</b> , "APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth," Journal of Experimental Medicine, Vol. 188, No. 6, pp. 1185-1190 (1998)	
	C67	<b>Halpern et al.</b> , "Chronic Administration of Belimumab, a BLyS Antagonist, Decreases Tissue and Peripheral Blood B-Lymphocyte Populations in Cynomolgus Monkeys: Pharmacokinetic, Pharmacodynamic, and Toxicologic Effects," Toxicological Sciences, Vol. 91, No. 2, pp. 586-599 (2006)	
	C68	<b>Hawley-Nelson, et al.</b> , Focus, Vol. 15, p. 73 (1993)	
	C69	<b>Herrscher, R.F., et al.</b> , "The Immunoglobulin Heavy-chain Matrix-Associating Regions are Bound by Bright $\alpha$ B Cell-Specific Trans-Activator That Describes A New DNA-Binding Protein Family," Genes & Development, Vol. 9, pp. 30607-3082 (1995)	
	C70	<b>Hillier, et al.</b> , GenBank Report for Accession No. H47097, August 16, 1995	
	C71	<b>Hill-Perkins, Possee, J.</b> Gen Virol., Vol. 71, pp. 971-976 (1990)	
	C72	<b>Holloway, M.P. and R.J. Bram</b> , "A Hydrophobic Domain of $Ca^{2+}$ Modulating Cyclophilin Ligand Modulates Calcium Influx Signaling in T Lymphocytes," The Journal of Biological Chemistry, Vol. 271, No. 15, pp. 8549-8552 (1996)	
	C73	<b>Holloway, M.P. and R.J. Bram</b> , "Co-localization of Calcium-modulating Cyclophilin Ligand with Intracellular Calcium Pools," Journal of Biological Chemistry, Vol. 273, No. 26, pp. 16346-16350 (June 26, 1992)	
	C74	<b>Holm</b> , Nuc. Acids Res., Vol. 14, pp. 3075-3087 (1986)	
	C75	<b>Hopp, Woods</b> Proc. Nat. Acad. Sci., Vol. 78, pp. 3824-3828 (1981)	
	C76	<b>Hoth, M. and R. Penner</b> , "Calcium Release-Activated Calcium Current in Rat Mast Cells, Journal of Physiology, Vol. 465, pp. 359-386 (1993)	
	C77	<b>Houdebine</b> , "Transgenic Animal Bioreactors," Transgenic Research, Vol. 9, pp. 305-320 (2000)	
	C78	<b>Houdebine, L-M.</b> , 2002, Journal of Biotechnology, Vol. 98, p. 145-160.	
	C79	<b>Huard, et al.</b> , "BAFF Production by Antigen-Presenting Cells Provides T Cell Co-Stimulation," International Immunology, Vol. 16, No. 3, pp. 467-475 (2004)	
	C80	<b>Huard, et al.</b> , "T Cell Costimulation by the TNF Ligand BAFF," Journal of Immunology, Vol. 167, pp. 6225-6231 (2001)	
	C81	<b>Hubbard, M.J., et al.</b> , Vol. 28, pp. 1868-1874 (1989)	
	C82	<b>Hymowitz, et al.</b> , "Structures of APRIL-Receptor Complexes," Journal of Biological Chemistry, Vol. 280, No. 8, pp. 7218-7227 (2005)	
	C83	<b>Ibragimova, G., et al.</b> , "Stability of the B-Sheet of the WW Domain: A Molecular Dynamics Simulation Study," Biophysical Journal, Vol. 77, pp. 2192-2198 (1999)	
	C84	<b>Idemura, J.</b> Mol Biol., Vol. 158, pp. 573-597 (1982)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAZ/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/627,206
				<b>Filing Date</b>	July 27, 2000
				<b>First Named Inventor</b>	Jane A. Gross
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Robert A. Zeman
Sheet	9	of	15	<b>Attorney Docket Number</b>	05558.0026.CPUS03

	C85	<b>Imboden, J.B., et al.</b> , "The Antigen Receptor on a Human T Cell Line Initiates Activation by Increasing Cytoplasmic Free Calcium" Journal of Immunology, Vol. 134, No. 2, pp. 663-665 (February 1985)	
	C86	<b>Inbar, et al.</b> , Proc. Natl. Acad. Sci., Vol. 69, p. 2659 (1972)	
	C87	<b>InNEXUS Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies,</b> " [Online] Retrieved from Scientific Blogging, XP-002515036, (2008, pp. 1-2, Presentation American Association for Cancer Research, San Diego, CA, 2008, pp. 1-14	
	C88	Interlocutory Decision in Opposition Proceedings of EP 00902354 dated November 30, 2007	
	C89	International Preliminary Report on Patentability of PCT/US00/00396 dated June 19, 2001	
	C90	International Preliminary Report on Patentability of PCT/US2006/031277 dated August 9, 2005	
	C91	International Preliminary Report on Patentability of PCT/US2007/068982 dated November 27, 2008	
	C92	International Preliminary Report on Patentability of PCT/US98/04270 dated January 5, 1999	
	C93	International Search Report for WO 99/12964 dated 04/13/1999	
	C94	International Search Report of PCT/US00/00396 dated July 7, 2000	
	C95	International Search Report of PCT/US2006/031274, dated June 1, 2007 (0031.00PC01) WO 2007/019573	
	C96	International Search Report of PCT/US2006/031277, dated May 9, 2007 (0033.00PC01) (WO 2007/019575)	
	C97	International Search Report of PCT/US2007/068982 dated 03/03/2008	
	C98	International Search Report of PCT/US2008/080177 dated February 26, 2009	
	C99	International Search Report of PCT/US98/04270 dated August 21, 1998	
	C100	<b>Jones, et al.</b> , Nature, Vol. 321, p. 522 (1986)	
	C101	<b>Kalled, S.L., et al.</b> , "BAFF; B Cell Survival Factor and Emerging Therapeutic Target for Autoimmune Disorders," Expert Opin. Ther. Targets, Vol. 7, No. 1, pp. 115-123 (2003)	
	C102	<b>Karttunen, J., and N. Shastri</b> , "Measurement of Ligand-induced Activation in Single Viable T Cells Using the lacZ Reporter Gene," Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 3972-3976 (May 1991)	
	C103	<b>Kelly, K.</b> , "APRIL/TRDL-1, a Tumor Necrosis Factor-Like Ligand, Stimulates Cell Death," Cancer Research, Vol. 60, pp. 1021-1027 (2000)	
	C104	<b>Kohler, et al.</b> , Nature, Vol. 257, p. 495 (1975)	
	C105	<b>Kolb, et al.</b> , "Insertion of a Foreign Gene into the Beta-casein Locus by Cre-mediated Site-specific Recombination, Gene, Vol. 227, pp. 21-31 (1999)	
	C106	<b>Korganow, et al.</b> , Immunity, Vol. 10, pp. 451-461 (1999)	
	C107	<b>Kyte, Doolittle</b> , J. Mol. Biol., Vol. 157, pp. 105-142 (1982)	
	C108	<b>Larrick, et al.</b> , "Methods: A Companion to Methods in Enzymology, Vol. 2, p. 106 (1991)	
	C109	<b>Lazar et al.</b> , "Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities" Molecular and Cellular Biology 8(3) 1247-1252 (1988)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAZ/**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/627,206
				<b>Filing Date</b>	July 27, 2000
				<b>First Named Inventor</b>	Jane A. Gross
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Robert A. Zeman
Sheet	10	of	15	<b>Attorney Docket Number</b>	05558.0026.CPUS03

	C110	<b>Leiter, et al.</b> , "Mice with targeted gene disruptions or gene insertions for diabetes research; problems, pitfalls, and potential solutions," <i>Diabetologia</i> , Vol. 45, pp. 296-308 (2002)	
	C111	<b>Lin et al.</b> , "Structure-Function Relationships in Glucagon: Properties of Highly Purified Des-His1, Monoiodo-, and [Des-Asn 28,Thr29](homoserine lactone27)-glucagon" <i>Biochemistry USA</i> 14:1559-1563 (1975)	
	C112	<b>Liu, J., et al.</b> , "Calcineurin is a Common Target of Cyclophilin-Cyclosporin A FKBP-FK506 Complexes," <i>Cell</i> , Vol. 66, pp. 807-815 (August 13, 1991)	
	C113	<b>Lonberg, et al.</b> , <i>Nature</i> , Vol. 368, p. 856 (1994)	
	C114	<b>Losman, et al.</b> , <i>Int. J. Cancer</i> , Vol. 46, p. 310 (1990)	
	C115	<b>Luckow, et al.</b> , <i>J. Virol.</i> , Vol. 67, pp. 4566-4579 (1993)	
	C116	<b>Mariette, X., et al.</b> , "The Level of BLyS (BAFF) Correlates with the Titre of Autoantibodies in Human Sjogren's Syndrome," <i>Annals of the Rheumatic Diseases</i> , Vol. 62, pp. 168-171 (2003)	
	C117	<b>Martino</b> , FierceBiotech, Press Release: ZymoGenetics and Serono to Begin TACI-Ig Clinical Studies in B-cell Malignancies, pp. 1-4, 11/9/06	
	C118	<b>Mathey-Prevot, et al.</b> , <i>Mol. Cell. Biol.</i> , Vol. 6, pp. 4133-4135 (1986)	
	C119	<del><b>Marck</b>, 17th Edition, Section 6 Pulmonary Disorders, pp. 568-569</del>	
	C120	<b>Miller, et al.</b> , GenBank Report for Accession No. R24371, April 20, 1995	
	C121	<b>Mishra</b> , GenBank Report for Accession No. V64412, March 1, 1999	
	C122	<b>Moon and RYU</b> , "TACI: Fc Scavenging B Cell Activating Factor (BAFF) Alleviates Ovalbumin-Induced Bronchial Asthma in Mice," <i>Exp. Mol. Med.</i> , Vol. 39, No. 3, pp. 343-352 (June 2007)	
	C123	<b>Munaf, et al.</b> , "Safety, Pharmacokinetics and Pharmacodynamics of Atacicept in Healthy Volunteers," <i>Eur J Clin Pharmacol</i> , Vol. 63, pp. 647-656 (April 2, 2007)	
	C124	<b>Neumann, et al.</b> , <i>Embo J.</i> , Vol. 1, pps. 841-845 (1982)	
	C125	<b>Ng, et al.</b> , "B Cell-Activating Factor Belonging to the TNF Family (BAFF)-R Is the Principal BAFF Receptor Facilitating BAFF Costimulation of Circulating T and B Cells," <i>Journal of Immunology</i> , Vol. 173, pp. 807-817 (2004)	
	C126	<b>Nilsson, et al.</b> , <i>Embo J.</i> , Vol. 4, p 1075, (1985)	
	C127	<b>Nilsson, et al.</b> , <i>Methods Enzymol.</i> , Vol. 198, p. 3 (1991)	
	C128	<b>Nisonoff, et al.</b> , <i>Biochem. Biophys.</i> , Vol. 89, p. 230 (1960)	
	C129	<b>Novake, Anne, J., et al.</b> , <i>Blood</i> , Vol. 103, No. 2, pp. 689-694 (2004)	
	C130	<b>O'Keefe, S.J., et al.</b> , "FK-506 and CsA-sensitive Activation of the Interleukin-2 Promoter by Calcineurin," <i>Nature</i> , Vol. 357, pp. 692-694 (June 25, 1992)	
	C131	<b>Orlandi, et al.</b> , <i>Proc. Natl. Acad. Sci.</i> , Vol. 86, p. 3833 (1989)	
	C132	<b>Pack, et al.</b> , <i>Bio/Technology</i> , Vol. 11, p. 1271 (1993)	
	C133	<b>Palacios, Steinemetz</b> , <i>Cell</i> , Vol. 41, pp. 727-734 (1985)	
	C134	<b>Panayi</b> , "The Pathogenesis of Rheumatoid Arthritis: From Molecules to the Whole Patient," <i>British Journal of Rheumatology</i> , Vol. 32, pp. 533-536 (1993)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAZ/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/627,206
				<b>Filing Date</b>	July 27, 2000
				<b>First Named Inventor</b>	Jane A. Gross
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Robert A. Zeman
Sheet	11	of	15	<b>Attorney Docket Number</b>	05558.0026.CPUS03

	C135	<b>Patel, et al.</b> , "Engineering an APRIL-specific B Cell Maturation Antigen," Journal of Biological Chemistry, Vol. 279, No. 16, pp. 16727-16735 (April 16, 2004)	
	C136	<del><b>Pera-Rossi, C., et al.</b>, "An Exploratory Dose Escalating Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Apremilast in Patients with Systemic Lupus Erythematosus," pp. 1-93</del>	
	C137	<b>Perez-Melgosa, et al.</b> , J. Immunol., Vol. 163, p. 1123-27 (1999)	
	C138	<b>Porter</b> , Biochem. J., Vol. 73, p. 119 (1959)	
	C139	<b>Premack, B.A., et al.</b> , "Activation of $Ca^{2+}$ Current in Jurkat T Cells Following the Depletion of $Ca^{2+}$ Stores by Microsomal $Ca^{2+}$ -ATPase Inhibitors," Journal of Immunology, Vol. 152, pp. 5226-5240 (1994)	
	C140	<b>Putney, J.W., Jr., and G.St. J. Bird</b> , "The Signal for Capacitative Calcium Entry, Cell, Vol. 75, pp. 199-201 (October 22, 1993)	
	C141	<b>Ramakrishnan</b> and Scheid, "Diagnosis and Management of Acute Pyelonephritis in Adults," American Family Physician, Vol. 71, No. 5, pp. 933-942 (March 1, 2005)	
	C142	<b>Ramanujam, M. et al.</b> , "Mechanism of Action of Transmembrane Activator and Calcium Modulator Ligand Interactor-Ig in Murine Systemic Lupus Erythematosus," J. Immunol., Vol. 173, 3524-3534 (2004)	
	C143	<b>Ramser, et al.</b> , GenBank Report for Accession No. AL353996 (2000)	
	C144	<b>Raymond, et al.</b> , Yeast, Vol. 14, pp. 11-23 (1998)	
	C145	<b>Richardson, P., et al.</b> , "A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma," N Engl J Med, Vol. 348, No. 26, pp. 2609-2617 (2003)	
	C146	<b>Roitt, I., et al.</b> , "Autoimmunity and Autoimmune Disease - 27," Immunology, Fourth Edition, pp. 271-272 (1996)	
	C147	<b>Roschke, V., et al.</b> , "BLyS and APRIL Form Biologically Active Heterotrimers That Are Expressed in Patients with Systemic Immune-Based Rheumatic Diseases," Journal of Immunology, Vol. 169, pp. 4314-4321 (2002)	
	C148	<b>Rudinger, J.</b> , "Characteristics of the Amino Acids as Components of Peptide Hormone Sequence," Peptide Hormones, University Park Press, Baltimore, pp. 1-7, (June 1976)	
	C149	<b>Ryan, M., et al.</b> , "Antibody Targeting of B-Cell Maturation Antigen on Malignant Plasma Cells," Molecular Cancer Therapeutics, Vol. 16, No. 11, US American Association of Cancer Research pp. 3009-3018 (November, 2007)	
	C150	<b>Santee, S.M., and L.B. Owen-Schaub</b> , "Human Tumor Necrosis Factor Receptor p75/80 (CD120B) Gene Structure and Promoter Characterization," The Journal of Biological Chemistry, Vol. 271, No. 35, pp. 21151-21159 (1996)	
	C151	<b>Scatchard Ann. Ny. Acad. Sci.</b> , Vol. 51, p. 660 (1949)	
	C152	<b>Schwartz et al.</b> , "A Superactive Insulin: [B10-Aspartic acid] insulin (human)" Proc Natl Acad Sci USA 84:6408-6411 (1987)	
	C153	<b>Sethi, S., et al.</b> , "Oxidized Omega-3 Fatty Acids in Fish Oil Inhibit Leukocyte-Endothelial Interactions Through Activation of Pparg," Blood, Vol. 100, No. 4, pp. 1340-1346 (2002)	
	C154	<b>Sigmund, C.</b> , June 2000, Arterioscler. Thromb. Vasc. Biol., p. 1425-1429	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAZ/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/627,206
				<b>Filing Date</b>	July 27, 2000
				<b>First Named Inventor</b>	Jane A. Gross
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Robert A. Zeman
Sheet	12	of	15	<b>Attorney Docket Number</b>	05558.0026.CPUS03

	C155	Silverman, G.J., et al., "B Cell Modulation in Rheumatology," Current Opinion in Pharmacology - Cancer/Immunomodulation 200708 GB, Vol. 7, No. 4, pp. 426-433 (August 4, 2007)	
	C156	Singer, et al., J. Immun., Vol. 150, p. 2844 (1993)	
	C157	Sinkar, et al., J. Biosci., Vol. 11, pp. 47-58 (1987)	
	C158	Sipos, L., et al., Eur. J. Biochem., Vol. 213, pp. 1333-1340 (1993)	
	C159	Smith, et al., "The TNF Receptor Superfamily of Cellular and Viral Proteins" ACTIVATION, COSTIMULATION AND DEATH Vol. 76, pp. 959 - 62 (1994)	
	C160	Smith, Johnson, Gene, Vol. 67, p. 31 (1988)	
	C161	Smith, T., et al., "The Challenges of Genome Sequene annotation or "The devil is in the details," Nature Biotechnology, Vol. 15, 1222-1223 (1997)	
	C162	Stein, et al., "Immunologic Markers in the Differential Diagnosis of Non-Hodgkins Lymphomas," Journal of Cancer Research and Clinical Oncology, Vol. 101, p. 29, Abstract (1981)	
	C163	Stohl, et al., "B Cell Depletion Therapy in Systemic Rheumatic Diseases: Different Strokes for Different Folks?" Clinical Immunology, Vol. 121, No. 1, pp. 1-12 (October 1, 2006)	
	C164	Strand V. et al., "Biologic Therapies in Rheumatology: Lessons Learned, Future Directions," Nat. Rev. Drug. Discov., Vol. 6, No. 1, 75-92 (2007)	
	C165	Stryer, L., "Flow of Genetic Information," Biochemistry Fourth Edicition, W.H. Freeman and Company, New York, pp. 111 (1996)	
	C166	Stuve, O., et al., "Clinical Stabilization and Effective B-lymphocyte Depletion in the Cerebrospinal Fluid and Peripheral Blood of a Patient with Fulminant Relapsing-Remitting Multiple Sclerosis," Archives of Neurology, Vol. 62, No. 10, pp. 1620-1623 (Oct. 2005)	
	C167	Sulkowski, Trends in Biochem, Vol. 1, p. 7 (1985)	
	C168	Suntharalingam G., et al., "Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412," N. Engl. J. Med., Vol. 355, 1018-1028 (2006)	
	C169	<del>Tak, P. P., et al., "Adalimumab in Patients with Rheumatoid Arthritis: A Multi-Center, double-Blind, Placebo-Controlled, Dose-Escalating, Single and Repeat Dose Study," pp. 1-36</del>	
	C170	Takashi, et al., Japanese Journal of Science, Vol. 28, No. 5, p p. 333-342, (Oct. 2005) Abstract	
	C171	Takebe, Y., et al., "SrdPromoter: an Efficient and Versatile Mammalian cDNA Expression System Composed of the Simian Virus 40 Early Promoter and the R-US Segment of Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat, Molecular and Cellular Biology, Vol. 8, No. pp. 466-472 (June 1988)	
	C172	Tashiro, K., et al., "Signal Sequence Trap: A Cloning Strategy for Secreted Proteins and Type I Membrane Proteins," Science, Vol. 261, pp. 600-603 (July 30, 1993)	
	C173	Taylor, et al., Int. Immun., Vol. 6, p. 579 (1994)	
	C174	Thompson, J., et al., "BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF," Science, Vol. 293, pp. 2108-2111 (2001)	
	C175	Truneh, A., et al., "Early Steps of Lymphocyte Activation Bypassed by Synergy Between Calcium Ionophores and Phorbol Ester, Nature, Vol. 313, pp. 318-320 (January 24, 1985)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAZ/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/627,206
				<b>Filing Date</b>	July 27, 2000
				<b>First Named Inventor</b>	Jane A. Gross
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Robert A. Zeman
Sheet	13	of	15	<b>Attorney Docket Number</b>	05558.0026.CPUS03

	C176	<b>Tsokos</b> , "Lymphocytes, Cytokines, Inflammation, and Immune Trafficking," Current Opinion in Rheumatology, Vol. 7, pp. 376-383 (1995)	
	C177	<b>Tuan, et al.</b> , Connect Tiss. Res., Vol. 34, pp. 1-9 (1996)	
	C178	<b>Varthakavi, Minocha</b> , J. Gen. Virol., Vol. 77, p. 1875 (1996)	
	C179	<b>Verweij, C.L., et al.</b> , "Cell Type Specificity and Activation Requirements for NFAT-1 (Nuclear Factor of Activated T-cells) Transcriptional Activity Determined by a New Method Using Transgenic Mice to Assay Transcriptional Activity of an Individual Nuclear Factor," Journal of Biological Chemistry, Vol. 265, No. 26, pp. 15788-15795 (September 15, 1990)	
	C180	<b>Von Bulow and R.J. Bram</b> , "Activation of the Transcription Factor NFAT by a Novel CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily," Blood, Vol. 90, No. 10, Suppl. 1, Part 1, pp. 246A-247 (1997)	
	C181	<b>Von Bulow, G.U., et al.</b> , "Molecular Cloning and Functional Characterization of Murine Transmembrane Activator and CAML Interactor (TACI) with Chromosomal Localization in Human and Mouse," Mammalian Genome, Vol. 11, pp. 628-632 (2000)	
	C182	<b>Vugmeyster, Y., et al.</b> , "A Soluble BAFF Antagonist, BR3-Fc, Decreases Peripheral Blood B Cells and Lymphoid Tissue Marginal Zone and Follicular B Cells in Cynomolgus Monkeys," American Journal of Pathology 200602 US, Vol. 168, No. 2, pp. 476-489 (February 2, 2006)	
	C183	<b>Wain-Hobson, et al.</b> , Gene, Vol. 13, pp. 355-364 (1981)	
	C184	<b>Wallach</b> , "TNF Ligand and TNF/NGF Receptor Families," Dept of Biological Chemistry, Weizmann Institute of Science, pp. 377-411 (2000)	
	C185	<b>Wang, et al.</b> , "TACI-Ligand Interactions are required for T Cell Activation and Collagen-Induced Arthritis in Mice," Nature Immunology, Vol. 2, No. 7, pp. 632-637 (2001)	
	C186	<b>Weiss, A., and D.R. Littman, et al.</b> , "Signal Transduction by Lymphocyte Antigen Receptors," Cell, Vol. 76, pp. 263-274 (January 28, 1994)	
	C187	<b>Wigler, et al.</b> , Cell, Vol. 14, p. 7 25 (1978)	
	C188	<b>Wilson-Rawls, J., et al.</b> , Virology, Vol. 201, pp. 66-76 (1994)	
	C189	<b>Wu, Y., et al.</b> , "Tumor Necrosis Factor (TNF) Receptor Superfamily Member TACI is a High Affinity Receptor for TNF Family Members APRIL and BLyS," The Journal of Biological Chemistry, Vol. 275, No. 45, pp. 35478-35485 (2000)	
	C190	<b>Yan, et al.</b> , Nature Immunol., Vol. 1, pp. 37-41 (2000)	
	C191	<b>Yang, M., et al.</b> , "B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells," Journal of Immunology, Vol. 175, US The Williams and Wilkins Co., Baltimore, pp. 2814-2824 (September 2005)	
	C192	<b>Yu, G., et al.</b> , "April and TALL-I and Receptors BCMA and TACI: System for Regulating Humoral Immunity," Nature, Vol. 1, No. 3, pp. 252-256 (2000)	
	C193	<b>Zhou, et al.</b> , Blood, Vol. 98, No. 11:808a, Abstract 3361 (2001)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAZ/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/627,206
				<b>Filing Date</b>	July 27, 2000
				<b>First Named Inventor</b>	Jane A. Gross
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Robert A. Zeman
Sheet	14	of	15	<b>Attorney Docket Number</b>	05558.0026.CPUS03

	C194	<b>Zhu, J., et al.</b> , "Plasma Cells and IL-4 in Chronic Bronchitis and Chronic Obstructive Pulmonary Disease," American Journal of Respiratory and Critical Care Medicine, Vol. 175, US American Lung Association, New York, NY Vol. 175, pp. 1125-1133 (June 2007)	
	C195	<b>Zweifach, A., and R.S. Lewis</b> , "Mitogen-regulated $CA^{2+}$ Current of T Lymphocytes is Activated by Depletion of Intracellular $CA^{2+}$ Stores," Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 6295-6299 (July 1993)	
	C196	U.S. Appl. No. 11/501,999 Final Office Action dated June 12, 2009	
	C197	U.S. Appl. No. 11/501,999 Final office action dated January 7, 2009	
	C198	U.S. Appl. No. 11/501,999 Non-final office action dated May 30, 2008	
	C199	U.S. Appl. No. 11/501,999 Restriction requirement dated February 13, 2008	
	C200	U.S. Appl. No. 11/502,134 Non-final office action dated March 12, 2009	
	C201	U.S. Appl. No. 11/502,134 Advisory Action Communication dated December 16, 2008	
	C202	U.S. Appl. No. 11/502,134 Final office action dated July 2, 2008	
	C203	U.S. Appl. No. 11/502,134 Non-final office action dated September 27, 2007	
	C204	U.S. Appl. No. 11/748,978 Final office action dated June 12, 2009	
	C205	U.S. Appl. No. 11/748,978 Final office action dated January 8, 2009	
	C206	U.S. Appl. No. 11/748,978 Non-final Office action dated May 30, 2008	
	C207	U.S. Appl. No. 11/748,978 Restriction requirement dated February 13, 2008	
	C208	U.S. Appl. No. 09/479,856 Restriction Requirement dated July, 28, 2000	
	C209	U.S. Appl. No. 09/569,245 Restriction Requirement dated September 07, 2001	
	C210	U.S. Appl. No. 09/569,245 Restriction Requirement dated April 10, 2002	
	C211	U.S. Appl. No. 09/569,245 Non-Final Office Action dated August 8, 2002	
	C212	U.S. Appl. No. 09/569,245 Final Office Action dated April 25, 2003	
	C213	U.S. Appl. No. 09/569,245 Advisory Action dated March 9, 2004	
	C214	U.S. Appl. No. 09/569,245 Non-Final Office Action dated August 6, 2004	
	C215	U.S. Appl. No. 09/569,245 Final office Action dated May 23, 2005	
	C216	U.S. Appl. No. 09/569,245 Non-Final Office Action dated September 12, 2006	
	C217	U.S. Appl. No. 09/569,245 Non-Final Office Action dated November 16, 2007	
	C218	U.S. Appl. No. 09/569,245 Final Office Action dated August 21, 2008	
	C219	U.S. Appl. No. 09/569,245 Non-Final Office Action dated February 13, 2009	
	C220	U.S. Appl. No. 11/458,968 Restriction Requirement dated March 23, 2009	
	C221	U.S. Appl. No. 11/458,968 Non-Final Office Action dated June 24, 2009	
	C222	U.S. Appl. No. 11/200,992 Non-Final Office Action dated March 21, 2008	
	C223	U.S. Appl. No. 11/200,992 Final Office Action dated December 15, 2008	
	C224	U.S. Appl. No. 11/242,294 Non-Final office action dated June 22, 2007	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAZ/**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	09/627,206
				<b>Filing Date</b>	July 27, 2000
				<b>First Named Inventor</b>	Jane A. Gross
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Robert A. Zeman
<b>Sheet</b>	15	<b>of</b>	15	<b>Attorney Docket Number</b>	05558.0026.CPUS03

	C225	U.S. Appl. No. 11/242,294 Final Office Action dated March 28, 2008	
	C226	U.S. Appl. No. 11/242,294 Notice of Allowance dated October 24, 2008	
	C227	U.S. Appl. No. 12/057,133 Restriction Requirement dated July 13, 2009	
	C228	U.S. Appl. No. 10/152,363 Restriction Requirement dated October 31, 2003	
	C229	U.S. Appl. No. 10/152,363 Non-final office action dated February 24, 2004	
	C230	U.S. Appl. No. 10/152,363 Final office action dated April 1, 2005	
	C231	U.S. Appl. No. 12/252,955 Restriction Requirement dated September 4, 2009	
	C232	U.S. Appl. No. 12/359,801 Notice of Allowance dated August 17, 2009	

<b>Examiner Signature</b>	/Robert Zeman/	<b>Date Considered</b>	07/06/2010
-------------------------------	----------------	----------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAZ/**